Effects of a Single Oral Megadose of Vitamin D3 on Inflammation and Oxidative Stress Markers in Overweight and Obese Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

• Published in: Diabetes, metabolic syndrome and obesity : targets and therapy metabolic syndrome and obesity : targets and therapy, 2021, Vol.14, p.525-534
• Main Authors: Pessoa Mamede, Laine de Carvalho Guerra, de Lima, Rafaela Lira Formiga Cavalcanti, Silva, Alexandre Sérgio, Rodrigues Pita, João Carlos Lima, Galdino Gomes, Nadjeanny Ingrid, de Sena, Elisama Araújo, Moraes Nobrega, Rhayra Priscila, Scarano Alcântara, João Otávio, Fontes de Souza, Julie Hanna, Cardoso, Glêbia Alexa, de Brito Alves, José Luiz, Rodrigues Gonçalves, Maria da Conceição
• Format: Report
• Language: English
• ISSN: 1178-7007; 1178-7007
• DOI: 10.2147/DMSO.S285597

AIMThe study aimed to evaluate the effects of vitamin D3 (VD3) supplementation on inflammation and oxidative stress markers in overweight and obese women with deficiency or insufficiency of vitamin D. METHODSTwenty-nine overweight or obese women who had a deficiency or insufficiency of vitamin D were placed into two groups according to VD3 intervention. Patients in the supplemented group received a single oral megadose of VD3 (VD3, n=14). Patients in placebo group received a single oral identical capsule without vitamin D (placebo, n = 15). Anthropometric and biochemical variables were assessed at baseline and after 4-weeks intervention. RESULTSAnthropometric variables (waist circumference, waist-hip ratio, waist-height ratio and body mass index) were similar between groups (p > 0.05). VD3 supplementation increased the serum levels of 25-hydroxyvitamin D (p=0.000), malondialdehyde (p=0.021) and C-reactive protein (p=0.043) in overweight and obese women. Additionally, VD3 supplementation reduced the serum levels of aspartate aminotransferase (AST, p=0.035), alanine aminotransferase (ALT, p